HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Immunotherapy of acute myelogenous leukemia (AML) in adults with the Nocardia rubra cell wall skeleton].

Abstract
The effect of immunotherapy with Nocardia rubra cell-wall skeleton (N-CWS) on the remission duration and survival of adults with acute myelogenous leukemia (AML) was studied in a prospective randomized controlled study. After having been induced into complete remission and consolidated, 73 patients were randomized either to maintenance chemotherapy or maintenance chemotherapy plus immunotherapy with N-CWS and irradiated allogeneic AML cells. Thirty-four patients in the chemotherapy group and 32 in the chemoimmunotherapy group were evaluable. Six months after the closure of the study, the immunotherapy showed a borderline beneficial effect on remission duration (p = 0.080) and on survival length (p = 0.098). When the data were analyzed at 42 months after entry, there was a borderline significant difference in remission duration (p = 0.066) between the two groups, prolonging the 50% remission period by 120 days, but no significant differences in survival length (p = 0.306), although the 50% survival was 168 days longer in the chemoimmunotherapy group. Thus, immunotherapy with N-CWS and irradiated allogeneic AML cells seems to be active in the treatment of adult AML when used for maintenance therapy in combination with chemotherapy.
AuthorsR Ohno, H Nakamura, Y Kodera, T Masaoka, K Yamada
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 13 Issue 4 Pt 2 Pg. 1264-9 (Apr 1986) ISSN: 0385-0684 [Print] Japan
PMID3524463 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)
Chemical References
  • Antigens, Neoplasm
  • Cell Wall Skeleton
  • Mucoproteins
  • cell wall skeleton, Nocardia
Topics
  • Adult
  • Antigens, Neoplasm (immunology)
  • Bone Marrow Transplantation
  • Cell Wall Skeleton
  • Combined Modality Therapy
  • Female
  • Humans
  • Leukemia, Myeloid, Acute (therapy)
  • Male
  • Mucoproteins (therapeutic use)
  • Nocardia (immunology)
  • Prospective Studies
  • Random Allocation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: